Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery (HEMOCOR)

This study has been completed.

Sponsor:

Information provided by:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

ClinicalTrials.gov Identifier:

NCT00825981

First received: January 16, 2009

Last updated: July 22, 2010

Last verified: July 2010

History of Changes

Tracking Information
First Received Date ^ICMJE	January 16, 2009
Last Updated Date	July 22, 2010
Start Date ^ICMJE	January 2009
Primary Completion Date	January 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00825981 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery
Official Title ^ICMJE	Not Provided
Brief Summary	Patients undergoing elective coronary artery bypass graft surgery (CABG) are treated with platelet inhibitors to reduce myocardial infarction and mortality.However, this can increase perioperative bleeding. A retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective CABG since 5 years. The aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Probability Sample
Study Population	coronary artery bypass graft
Condition ^ICMJE	Coronary Disease
Intervention ^ICMJE	Other: screening coagulation abnormalities if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
Study Group/Cohort (s)	coronary artery bypass graft patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass Intervention: Other: screening coagulation abnormalities
Publications *	Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005;31(4):426-40.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Estimated Enrollment ^ICMJE	100
Completion Date	March 2010
Primary Completion Date	January 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: coronary artery bypass graft surgery with or without cardiopulmonary bypass Exclusion Criteria: emergency; redo cardiac surgery; combined cardiac surgery; patients with renal insufficiency; patients with acquired coagulation abnormalities
Gender	Both
Ages	18 Years to 90 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Belgium

Administrative Information
NCT Number ^ICMJE	NCT00825981
Other Study ID Numbers ^ICMJE	2008/10DEC/350
Has Data Monitoring Committee	No
Responsible Party	Mona Momeni, MD, Cliniques Universitaires saint Luc
Study Sponsor ^ICMJE	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Verification Date	July 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top